Stock Code: 002038 Stock Abbreviation: Double-Crane Pharmaceutical Announcement Number: 2026-006
Beijing Double-Crane Pharmaceutical Co., Ltd. Announcement of Resolutions from the Ninth Meeting of the Ninth Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.
I. Convening of the Board Meeting
The Ninth Meeting of the Ninth Board of Directors of Beijing Double-Crane Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held on April 27, 2026, in the company's headquarters meeting room (4th Floor, Building 1, Biyuntongyuan, Haidian District, Beijing) via on-site meeting. The meeting notice was delivered via communication on April 16, 2026. The meeting was chaired by Chairman Xu Mingbo. Six directors were expected to attend, and six directors actually attended. The convening procedures and voting methods of this meeting comply with the "Company Law of the People's Republic of China (2023 Revision)" (hereinafter referred to as the "Company Law") and other laws and regulations, as well as the Articles of Association. The meeting was legal and valid.
II. Matters for Deliberation
The following proposals were deliberated and voted upon:
(I) Proposal on the 2025 Annual Report and Summary was approved.
After deliberation, the Board of Directors believes that the Company's "2025 Annual Report" and "2025 Annual Report Summary" comply with laws and regulations. The content of the reports truthfully, accurately, and completely reflects the Company's operating conditions in 2025, with no false records, misleading statements, or major omissions.
For details, please refer to the "2025 Annual Report" and "2025 Annual Report Summary" (Announcement Number: 2026-004) disclosed by the Company on the Juchao Information Network (https://www.cninfo.com.cn) on the same day. The "2025 Annual Report" and "2025 Annual Report Summary" were also published in the "China Securities Journal" and "Securities Daily."
This proposal has been reviewed and approved by the Fourth Meeting of the Ninth Board of Directors' Audit Committee in 2026 and needs to be submitted to the 2025 Annual Shareholders' Meeting for approval.
Voting results: 6 valid votes, 6 in favor, 0 against, 0 abstentions.
(II) Proposal on the 2025 Board of Directors' Work Report was approved.
In accordance with relevant laws, regulations, and the Articles of Association, the Company's Board of Directors has summarized its work in 2025 and compiled the "2025 Board of Directors' Work Report." Chairman Xu Mingbo delivered the report on behalf of the Board. All attending directors unanimously agreed that the report objectively and truthfully reflects the various tasks undertaken by the Board of Directors in 2025. The independent directors present submitted their "Independent Directors' 2025 Performance Report" at the meeting, which will be presented at the Company's 2025 Annual Shareholders' Meeting.
For details, please refer to the "2025 Board of Directors' Work Report" and "Independent Directors' 2025 Performance Report" disclosed by the Company on the Juchao Information Network (https://www.cninfo.com.cn).
This proposal needs to be submitted to the 2025 Annual Shareholders' Meeting for approval.
(III) Proposal on the 2025 General Manager's Work Report was approved.
In accordance with the "Company Law" and other laws, regulations, and normative documents, the Company's General Manager summarized the work in 2025 and delivered the "2025 General Manager's Work Report."
(IV) Proposal on the 2025 Financial Report was approved.
In accordance with the "Company Law," "Articles of Association," and other regulations, the Company's management summarized the company's operating conditions and budget execution in 2025. The Board of Directors believes that the Company's "2025 Financial Report" objectively and truthfully reflects the Company's operating conditions in 2025. This proposal has been reviewed and approved by the Fourth Meeting of the Ninth Board of Directors' Audit Committee in 2026.